In esophageal cancer, IGFBP2 overexpression is associated with shorter disease-free intervals and treatment resistance, and the knockdown of IGFBP2 sensitizes esophageal adenocarcinoma cells to cisplatin in a serum-dependent manner [28]. Here, IGFBP2 is linked to esophageal cancer.